Department of Radiation Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,Chin (Wang WH,Department of Radiotherapy,Cancer Hospital of Peking University)
Objective To investigate the value of post-mastectomy radiotherapy (PMRT) in patients with T3N0 breast cancer (BC) who were treated with modified radical mastectomy (MRM). Methods A retrospective analysis was performed on the clinical data of BC patients treated with MRM from 1997 to 2014.The inclusion criteria were as follows:(1) female patients;(2) pathological diagnosis of invasive BC;(3) tumor volume greater than 5 cm without axillary lymph node metastasis;(4) the patients who received no neoadjuvant chemotherapy or endocrine therapy and had no distant metastasis or other second primary cancers. A total of 78 patients met the inclusion criteria. Forty patients (51%) received PMRT and sixty-seven patients (86%) received adjuvant chemotherapy. The Kaplan-Meier method was used to calculate overall survival (OS), disease-free survival (DFS)(DFS), and local-regional recurrence (LRR) rates, and survival differences between groups were analyzed by the log-rank test. Results The median follow-up time was 79 months (6-232 months). For all patients, the 5-year OS, DFS, and LRR rates were 89%, 87%, and 2%, respectively. The 5-year DFS, OS and LRR rates for radiotherapy group were 84%, 84% and 0%, respectively, versus 91%(P=0.641), 96%(P=0.126), and 5% for non-radiotherapy group. Only estrogen receptor/progesterone receptor (ER/PR) status and molecular type had significant impacts on DFS (P=0.002 and 0.031, respectively). One patient in non-radiotherapy group had chest wall recurrence. Conclusions MRM is effective in reducing LRR in T3N0M0 BC patients. Only ER/PR status and molecular type significantly influence DFS. Effective systemic therapy may be helpful for some T3N0 patients to avoid chest wall and supraclavicular radiotherapy after MRM, but large-sample studies are needed to further confirm this conclusion.
Li Shuai,Wang Shulian,Tang Yu et al. Clinical value of radiotherapy in 78 patients with pT3N0M0 breast cancer after modified radical mastectomy[J]. Chinese Journal of Radiation Oncology, 2017, 26(10): 1151-1155.
[1] Goulart J,Truong P,Woods R,et al. Outcomes of node-negative breast cancer 5 centimeters and larger treated with and without postmastectomy radiotherapy[J].Int J Radiat Oncol Biol Phys,2011,80(3):758-764.DOI:10.1016/j.ijrobp.2010.02.014.
[2] Helinto M,Blomqvist C,Heikkil P,et al. Post-mastectomy radiotherapy in pT3N0M0 breast cancer:is it needed?[J].Radiother Oncol,1999,52(3):213-217.DOI:10.1016/S0167-8140(99)00099-7.
[3] Senkus E,Kyriakides S,Ohno S,et al. Primary breast cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2015,26 Suppl 5:v8-v30.DOI:10.1093/annonc/mdv298.
[4] NCCN. Breast cancer 2016,version 2[EB/OL][2017-04-19].http://www.nccn.org.
[5] Yan WS,Christos P,Nori D,et al. Is there a cause-specific survival benefit of postmastectomy radiation therapy in women younger than age 50 with T3N0 invasive breast cancer? A SEER database analysis:outcomes by receptor status/race/ age:analysis using the NCI Surveillance,Epidemiology,and End Results (SEER) database[J].Am J Clin Oncol,2013,36(6):552-557.DOI:10.1097/COC.0b013e31825 d529b.
[6] Johnson ME,Handorf EA,Martin JM,et al. Postmastectomy radiation therapy for T3N0:a SEER analysis[J].Cancer,2014,120(22):3569-3574.DOI:10.1002/cncr.28865.
[7] Early Breast Cancer Trialists′ Collaborative Group (EBCTCG),Davies C,Godwin J,et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen:patient-level meta-analysis of randomised trials[J].Lancet,2011,378(9793):771-784.DOI:10.1016/S0140-6736(11)60993-8.
[8] Early Breast Cancer Trialists′ Collaborative Group (EBCTCG),Peto R,Davies C,et al. Comparisons between different polychemotherapy regimens for early breast cancer:meta-analyses of long-term outcome among 100 000 women in 123 randomised trials[J].Lancet,2012,379(9814):432-444.DOI:10.1016/S0140-6736(11)61625-5.
[9] Floyd SR,Buchholz TA,Haffty BG,et al. Low local recurrence rate without postmastectomy radiation in node-negative breast cancer patients with tumors 5 cm and larger[J].Int J Radiat Oncol Biol Phys,2006,66(2):358-364.DOI:10.1016/j.ijrobp.2006.05.001.
[10] Alphonse GT,Jeong JH,Mamounas EP,et al.Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy,with or without adjuvant systemic therapy and without radiotherapy:results from five national surgical adjuvant breast and bowel project randomized clinical trials[J].J Clin Oncol,2006,24(24):3927-3932.DOI:10.1200/JCO.2006.06.9054.
[11] Overgaard M,Hansen PS,Overgaard J,et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy[J].N Engl J Med,1997,337(14):949-955.DOI:10.1056/NEJM199710023371401.
[12] Overgaard M,Jensen MB,Overgaard J,et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen:Danish Breast Cancer Cooperative Group DBCG 82c randomised trial[J].Lancet,1999,353(9165):1641-1648.DOI:10.1016/S0140-6736(98) 09201-0.
[13] Carey LA,Perou CM,Livasy CA,et al. Race,breast cancer subtypes,and survival in the Carolina Breast Cancer Study[J].JAMA,2006,295(21):2492-2502.DOI:10.1001/jama.295.21.2492.
[14] Nguyen PL,Taghian AG,Katz MS,et al. Breast cancer subtype approximated by estrogen receptor,progesterone receptor,and HER-2 is associated with local and distant recurrence after breast-conserving therapy[J].J Clin Oncol,2008,26(14):2373-2378.DOI:10.1200/JCO.2007.14.4287.
2017, Vol. 26 
